首页 › 弥漫性大B细胞淋巴瘤 › 弗吉尼亚州 › Richmond
Richmond VA 弥漫性大B细胞淋巴瘤临床试验
11项针对 弥漫性大B细胞淋巴瘤的研究正在 Richmond及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Virginia Cancer Institute ( Site 0148), Richmond
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
招募中2 期
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Virginia Commonwealth University-Massey Cancer Center, Richmond
A Study of ARC-02 in B-cell NHL
招募中1 期
- Massey Cancer Center, Richmond
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
招募中2 期
- VCU Massey Comprehensive Cancer Center, Richmond
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Virginia Commonwealth University Massey Cancer Center, Richmond
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
招募中1/2 期
- VCU Massey Comprehensive Cancer Center, Richmond
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Virginia Commonwealth University-Massey Cancer Center, Richmond
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
招募中2 期
- Virginia Commonwealth University, Richmond
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY20 项研究
- Baldwin Park, CA19 项研究
- Los Angeles, CA18 项研究
- Houston, TX18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI17 项研究
- Nashville, TN17 项研究
- Boston, MA17 项研究
- Philadelphia, PA15 项研究
- Durham, NC15 项研究
- Portland, OR15 项研究
- Cleveland, OH13 项研究
Richmond的其他研究
- 乳腺癌27 项研究
- 非小细胞肺癌26 项研究
- 前列腺癌19 项研究
- 心力衰竭17 项研究
- 肺癌15 项研究
- 心血管疾病13 项研究
- 头颈鳞状细胞癌13 项研究
- 结直肠癌13 项研究
- 癌症（所有类型）12 项研究
- 转移性癌症12 项研究
- 脂肪性肝病11 项研究
- 黑色素瘤11 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。